Alba Therapeutics Corporation announced today that for the first time, a European patient with active celiac disease has been enrolled in its clinical trial to investigate a treatment for the disease. Alba has enrolled and randomized the newly diagnosed patient from Spain in an eight-week Phase IIb trial with oral larazotide acetate, a tight junction regulator, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while assessing improvement in the clinical signs and symptoms of celiac disease.
(1) Green, P, and Cellier, C, Review Article, Medical Progress, Celiac Disease, N ENGL J MED 2007;357:1731-43
For more information about Alba’s clinical trials, please visit the www.clinicaltrials.gov web site and search for Alba Therapeutics.
Media: Mariesa Kemble Sam Brown Communications 608-850-4745 firstname.lastname@example.org Corporate: Wendy Perrow, MBA Alba Therapeutics Corporation 410-878-9850 email@example.com http://www.albatherapeutics.com
---------------------- Author Information: John Libonati, Philadelphia, PA Publisher, Glutenfreeworks.com. Editor & Publisher, Recognizing Celiac Disease. John can be reached by e-mail here.